Regulation of RASSF by Non-coding RNAs in Different Cancers: RASSFs As Masterminds of Their Own Destiny As Tumor Suppressors and Oncogenes

Overview

Journal Noncoding RNA Res

Date 2022 Jun 15

PMID 35702574

Authors

Ammad Ahmad Farooqi

Gulnara Kapanova

Abay Z Kussainov

Zaure Datkhayeva

Karlygash Raganina

Bolat N Sadykov

Affiliations

Soon will be listed here.

Abstract

Ras-association domain family (RASSF) proteins are tumor suppressors and have gained phenomenal limelight because of their mechanistic role in the prevention/inhibition of carcinogenesis and metastasis. Decades of research have demystified wide ranging activities of RASSF molecules in multiple stages of cancers. Although major fraction of RASSF molecules has tumor suppressive roles, yet there is parallel existence of proof-of-concept about moonlighting activities of RASSF proteins as oncogenes. RASSF proteins tactfully rewire signaling cascades for prevention of cancer and metastasis but circumstantial evidence also illuminates oncogenic role of different RASSF proteins in different cancers. In this review we have attempted to provide readers an overview of the complex interplay between non-coding RNAs and RASSF proteins and how these versatile regulators shape the landscape of carcinogenesis and metastasis.

References

Stoner S, Liu K, Andrews E, Liu M, Arimoto K, Yan M . The RUNX1-ETO target gene RASSF2 suppresses t(8;21) AML development and regulates Rac GTPase signaling. Blood Cancer J. 2020; 10(2):16. PMC: 7005177. DOI: 10.1038/s41408-020-0282-9. View

Zhang C, Kang Y, Kong F, Yang Q, Chang D . Hotspots and development frontiers of circRNA based on bibliometric analysis. Noncoding RNA Res. 2022; 7(2):77-88. PMC: 8956961. DOI: 10.1016/j.ncrna.2022.03.001. View

Volinia S, Calin G, Liu C, Ambs S, Cimmino A, Petrocca F . A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006; 103(7):2257-61. PMC: 1413718. DOI: 10.1073/pnas.0510565103. View

Cui S, Hu X, Yan Y . Wnt/β-catenin signaling pathway participates in the effect of miR-626 on oral squamous cell carcinoma by targeting RASSF4. J Oral Pathol Med. 2021; 50(10):1005-1017. DOI: 10.1111/jop.13216. View

Kim S, Jin H, Meng R, Kim D, Liu Y, Chai O . Activating Hippo Pathway via Rassf1 by Ursolic Acid Suppresses the Tumorigenesis of Gastric Cancer. Int J Mol Sci. 2019; 20(19). PMC: 6801984. DOI: 10.3390/ijms20194709. View

De Smedt E, Maes K, Verhulst S, Lui H, Kassambara A, Maes A . Loss of RASSF4 Expression in Multiple Myeloma Promotes RAS-Driven Malignant Progression. Cancer Res. 2017; 78(5):1155-1168. DOI: 10.1158/0008-5472.CAN-17-1544. View

Wang F, Feng Y, Li P, Wang K, Feng L, Liu Y . RASSF10 is an epigenetically inactivated tumor suppressor and independent prognostic factor in hepatocellular carcinoma. Oncotarget. 2015; 7(4):4279-97. PMC: 4826205. DOI: 10.18632/oncotarget.6654. View

Zheng L, Zhao Z, Rong L, Xue L, Song Y . RASSF6-TRIM16 axis promotes cell proliferation, migration and invasion in esophageal squamous cell carcinoma. J Genet Genomics. 2019; 46(10):477-488. DOI: 10.1016/j.jgg.2019.10.004. View

Wang T, Zhang H, Wang H, Chang C, Huang F, Zhang L . MiR-505-5p inhibits proliferation and promotes apoptosis of osteosarcoma cells via regulating RASSF8 expression. J BUON. 2021; 26(2):599-605. View

10.

Lakshmi Ch N, Sivagnanam A, Raja S, Mahalingam S . Molecular basis for RASSF10/NPM/RNF2 feedback cascade-mediated regulation of gastric cancer cell proliferation. J Biol Chem. 2021; 297(2):100935. PMC: 8339327. DOI: 10.1016/j.jbc.2021.100935. View

11.

Lee D, Park S, Sung K, Park J, Lee S, Park S . Mdm2 associates with Ras effector NORE1 to induce the degradation of oncoprotein HIPK1. EMBO Rep. 2011; 13(2):163-9. PMC: 3271333. DOI: 10.1038/embor.2011.235. View

12.

Braconi C, Huang N, Patel T . MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology. 2010; 51(3):881-90. PMC: 3902044. DOI: 10.1002/hep.23381. View

13.

Ko K, Jeong S, Lim J, Lee K, Lee M, Chi S . NORE1A directs apoptotic switch of TNF signaling through reciprocal modulation of ITCH-mediated destruction of TNFRI and BAX. Oncogene. 2020; 39(34):5675-5689. DOI: 10.1038/s41388-020-01392-y. View

14.

Mi Y, Zhang D, Jiang W, Weng J, Zhou C, Huang K . miR-181a-5p promotes the progression of gastric cancer via RASSF6-mediated MAPK signalling activation. Cancer Lett. 2017; 389:11-22. DOI: 10.1016/j.canlet.2016.12.033. View

15.

Wang H, Wu J, Meng X, Ying X, Zuo Y, Liu R . MicroRNA-342 inhibits colorectal cancer cell proliferation and invasion by directly targeting DNA methyltransferase 1. Carcinogenesis. 2011; 32(7):1033-42. DOI: 10.1093/carcin/bgr081. View

16.

Chen E, Yang F, He H, Lei L, Liu R, Du L . Decreased level of RASSF6 in sporadic colorectal cancer and its anti-tumor effects both in vitro and in vivo. Oncotarget. 2016; 7(15):19813-23. PMC: 4991420. DOI: 10.18632/oncotarget.7852. View

17.

Salzman J, Gawad C, Wang P, Lacayo N, Brown P . Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. PLoS One. 2012; 7(2):e30733. PMC: 3270023. DOI: 10.1371/journal.pone.0030733. View

18.

Jacquemart I, Springs A, Chen W . Rassf3 is responsible in part for resistance to mammary tumor development in neu transgenic mice. Int J Oncol. 2009; 34(2):517-28. View

19.

Zheng X, Dong Q, Zhang X, Han Q, Han X, Han Y . The coiled-coil domain of oncogene RASSF 7 inhibits hippo signaling and promotes non-small cell lung cancer. Oncotarget. 2017; 8(45):78734-78748. PMC: 5667994. DOI: 10.18632/oncotarget.20223. View

20.

Huang Y, Zhou C, Wen H, Chen Y, Xie Y, Lan X . Jianpi-Huayu Formula Inhibits Development of Hepatocellular Carcinoma by Regulating Expression of miR-602, Which Targets the Gene. Integr Cancer Ther. 2020; 19:1534735419900804. PMC: 7016307. DOI: 10.1177/1534735419900804. View